Corporate & Background
 Custom Manufacturing
 Business & Products
 Facilities & Strengths
 Ethics & Values
 Regulatory Submissions
 Investors & Financials
 Careers
 Locations & Contact
 Media Center
 Enquiry
      News & Events
 Divi’s Labs earns an Income of Rs.649 crores for 9M of FY10
 Divis Labs earns an Income of Rs.445 crores in H1 of FY10
 Divi's Labs earns a PAT of Rs.417 for the year 2008-09 And declares 1:1 bonus
 Divi's Labs PAT for 9 months
grows by 21% to Rs.309 crores
 Divi's Labs PAT for Q2 grows by
49% to Rs.135 crores
 Divi's Labs PAT for Q1 grows by
45% to Rs.94 crores
 Divi's Labs PAT for FY08 grows by 87% to Rs.348 crores
 Divi's Labs PAT for Q3 grows by 216% to Rs.99 crores
 Divi's Labs PAT for Q2 grows by 204% to Rs.91 crores
 Divi's Labs PAT for Q1 grows by 153% to Rs.65 crores
 Divi's Labs PAT for FY07
grows by 167% to Rs.186 crores
 Divi's Labs Q3 total income
 grows by 38% to Rs.152 crores
 Divis successful US-FDA inspection for Unit II
 Divi's Labs Q2 total income
 grows by 97% to Rs.165 crores.
 Divi's Labs Q1 total
 income grows by 142% at
 Rs.165 crores
 Divi's Laboratories earns a
 Net of Rs.19 crores
 on an Income of
 Rs.110 Crores in Q3
 Divis labs SEZs cleared
 Divis Laboratories earns a
 PBT of Rs.43 Crores in
 First-Half of FY06
 Divis Laboratories earns a
 total income of Rs.68
 Crores in Q1 of FY06
 Divis Laboratories earns a
 total income of Rs.365
 Crores in FY05
 Divis Laboratories earns a
 Net of Rs.105 Crores in Q3
 Divis Laboratories earns a
 PBT of Rs.45 Crores in
 First-Half of FY05
 Divis Laboratories earns a
 Net of Rs.14 Crores in Q1
 
Chairman Speech - 2009
Corporate Governance Report 2008-09
Company Profile
Established in the year 1990, with Research & Development as its prime fundamental, Divis Laboratories focussed on developing new processes ....Company Profile
Products Products
Generic APIs, Intermediates, Peptide Building Blocks, Carotenoids, Future Generics ....Products
R & D
The main aim of the Divis R&D Centers is to design, develop and optimize commercially viable synthetic processes for APIs and Intermediates of Generics .... R & D
 

Copyright © 2006, Divis Laboratories Ltd. All Rights Reserved         Web design by Sumudra